Trafficking of Indium-111-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Cancer
Patients undergoing immunotherapy for advanced cancer under IRB-approved protocols, who are
to receive immune cells in adoptive transfer, will have less than or equal to 50% of those
cells labeled with In-111-oxine and administered along with the remainder of their unlabeled
cells. They will then undergo gamma-camera imaging over the next 0-7 days and blood samples
and tumor sites which are accessible with minimal surgery (low-risk biopsy) may be sampled
in some patients for enumeration of radiolabeled cells. End-points will be tumor and normal
organ imaging and the amount of In-111 per gram of tissue in biopsies or per ml. of blood.
Interventional
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
United States: Federal Government
980033
NCT00026897
December 1997
December 2002
Name | Location |
---|---|
National Cancer Institute (NCI) | Bethesda, Maryland 20892 |